[ITEM]
31.01.2019

Programmu Asdv 020

56

Search among more than 1.000.000 user manuals and view them online in.pdf. By clicking any link or object on this website, you unconditionally agree and authorize us to process your personal data, including the use of cookies and other tracking technologies.

Fire - Fire Sprinkler. And Fire delivers it all. Download the functional demonstration version today. Fire now has the capability to handle a fire. Fire sprinkler design The FHC hydraulic calculation software has been used to design thousands of fire sprinkler systems through the world. From complex petrochemical plants, huge automated logistic facilities, aircraft hangers, manufacturing plants to a domestic house, whatever the project FHC will be able to help. Fire sprinkler software - hydraulic calculations fire sprinkler NEW & IMPROVED! 185Graph is a 1.85 graph based fire sprinkler hydraulic calculation software program specifically designed to graph sprinkler demand vs. Water supply. Welcome to the Simple Hydraulic Calculator (SHC for short).SHC is a powerful, flexible, and full featured fire sprinkler hydraulic calculation program designed from the ground up for automatic sprinkler system designers and engineers. Fire sprinkler system design software provides many commands to complete the sprinkler drawing. The sprinkler system design software can produce a tree, loop, grid, and slope sprinkler systems. Also, it can extract information from the sprinkler drawing for the hydraulic calculation and material listing automatically.

Double Vane Pump T67DC-Series Denison Hydraulics DTA supplies genuine Denison Hydraulics vane pumps, cartridge kits and other spare parts from stock. We hold a large stock of the T67 Series (Size DC) cartridge parts and pumps, brand new and genuinely made by the Parker Hannifin Vane Pump Division Europe. For a quote on the double vane pump T67DC 045 020 3R** A100 Is this not the pump you require? No need to worry! Just use the online to configure and select any other single, double or triple vane pump that meets your demands. The range of total volumetric displacement of the Denison Hydraulics T67 Series (Size DC) double vane pump T67DC is 55 ml/rev up to 258 ml/rev.

The total displacement of the double vane pump T67DC 045 020 3R** A100 is 209.5 ml/rev. Please find further hydraulic and technical details below. Double Vane Pump T67DC Cartridge Configuration Pump Section Series Type Size Cam Ring Displacement Pressure P1 (front) T7 Industrial D 045 145.7 ml/rev up to 240 bar P2 (rear) T6 Industrial C 020 63.8 ml/rev up to 275 bar Order a complete Denison Hydraulics double vane pump or just the parts you need. In the parts table below you may select the hydraulic parts you need. All parts we sell are genuine Denison Hydraulics by Parker Hannifin. We highly recommend to use genuine OEM parts only to ensure smooth operation and longer service life.

Parts of T67DC 045 020 3R** A100 Denison Hydraulics Model Description List Price Article No. T67DC 045 020 3R** A100 Double Vane Pump T67DC € 3,688.00 024-92412-0 CARTR T67DC UNIT D 045 CW S1 Cam Ring 'P1' 045 - Cartridge Kit € 1,315.30 S24-10859-0 CARTR T67DC UNIT C 020 CW S1 Cam Ring 'P2' 020 - Cartridge Kit € 952.70 S24-40234-0 SHAFT T67DC SPLIN 3 ASS Shaft Assembly #3 (incl. Bearing) € 266.20 S14-42518-0 KIT T67DC SEAL S1 Seal Class S1 - Seal Kit € 52.30 S24-10170-0.

Data Continue to Demonstrate the Durability and Safety of a Novel Gene Therapy Approach to Treating Wet AMD MENLO PARK, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today will present updated preclinical data on ADVM-022 in non-human primate models of wet AMD (wAMD). Vascular endothelial growth factor (VEGF) overexpression plays a key role in the development and progression of wAMD as well as other retinal conditions. ADVM-022 utilizes a novel vector designed to allow for intravitreal delivery of gene sequences encoding an inhibitor of VEGF activity.

Programmu Asdv 020

Intravitreal delivery is the route of administration for current standard of care anti-VEGF therapies, and is preferred over invasive surgical subretinal delivery of gene sequences. Mehdi Gasmi, Ph.D., Chief Science and Technology Officer at Adverum will present updated data today at 2 p.m. ET at the Targeting Ocular Disorders conference taking place in Boston, MA September 27–28, 2017. Previously reported data using the industry standard, laser-induced choroidal neovascularization (CNV) model in a non-human primate study demonstrated that a single intravitreal administration of ADVM-022 had comparable efficacy in reducing grade IV CNV lesions to an intravitreal injection of standard-of-care anti-VEGF therapies.

In addition, data showed durable anti-VEGF protein expression with therapeutic protein levels at least 20 weeks after a single intravitreal administration of ADVM-022. Today, additional pharmacokinetic data are being presented, demonstrating sustained expression for 52 weeks, with only mild ocular inflammation following a single intravitreal administration of ADVM-022 in one non-human primate.

In a separate study, sustained expression for at least seven months has been observed in several non-human primates. Adverum will continue to monitor these non-human primates to assess long-term durability of sustained expression of anti-VEGF protein after a single administration of ADVM-022.

“These additional long-term data continue to demonstrate sustained expression of anti-VEGF protein and that our novel vector enables intravitreal delivery,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “Today, patients living with wAMD undergo frequent intravitreal injections, which can increase the burden of managing this disease and poor compliance with treatment can lead to vision loss. We believe the potential of a single intravitreal injection will be of great benefit to patients and clinicians.” About Adverum Biotechnologies, Inc. Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

[/ITEM]
[/MAIN]
31.01.2019

Programmu Asdv 020

58

Search among more than 1.000.000 user manuals and view them online in.pdf. By clicking any link or object on this website, you unconditionally agree and authorize us to process your personal data, including the use of cookies and other tracking technologies.

Fire - Fire Sprinkler. And Fire delivers it all. Download the functional demonstration version today. Fire now has the capability to handle a fire. Fire sprinkler design The FHC hydraulic calculation software has been used to design thousands of fire sprinkler systems through the world. From complex petrochemical plants, huge automated logistic facilities, aircraft hangers, manufacturing plants to a domestic house, whatever the project FHC will be able to help. Fire sprinkler software - hydraulic calculations fire sprinkler NEW & IMPROVED! 185Graph is a 1.85 graph based fire sprinkler hydraulic calculation software program specifically designed to graph sprinkler demand vs. Water supply. Welcome to the Simple Hydraulic Calculator (SHC for short).SHC is a powerful, flexible, and full featured fire sprinkler hydraulic calculation program designed from the ground up for automatic sprinkler system designers and engineers. Fire sprinkler system design software provides many commands to complete the sprinkler drawing. The sprinkler system design software can produce a tree, loop, grid, and slope sprinkler systems. Also, it can extract information from the sprinkler drawing for the hydraulic calculation and material listing automatically.

Double Vane Pump T67DC-Series Denison Hydraulics DTA supplies genuine Denison Hydraulics vane pumps, cartridge kits and other spare parts from stock. We hold a large stock of the T67 Series (Size DC) cartridge parts and pumps, brand new and genuinely made by the Parker Hannifin Vane Pump Division Europe. For a quote on the double vane pump T67DC 045 020 3R** A100 Is this not the pump you require? No need to worry! Just use the online to configure and select any other single, double or triple vane pump that meets your demands. The range of total volumetric displacement of the Denison Hydraulics T67 Series (Size DC) double vane pump T67DC is 55 ml/rev up to 258 ml/rev.

The total displacement of the double vane pump T67DC 045 020 3R** A100 is 209.5 ml/rev. Please find further hydraulic and technical details below. Double Vane Pump T67DC Cartridge Configuration Pump Section Series Type Size Cam Ring Displacement Pressure P1 (front) T7 Industrial D 045 145.7 ml/rev up to 240 bar P2 (rear) T6 Industrial C 020 63.8 ml/rev up to 275 bar Order a complete Denison Hydraulics double vane pump or just the parts you need. In the parts table below you may select the hydraulic parts you need. All parts we sell are genuine Denison Hydraulics by Parker Hannifin. We highly recommend to use genuine OEM parts only to ensure smooth operation and longer service life.

Parts of T67DC 045 020 3R** A100 Denison Hydraulics Model Description List Price Article No. T67DC 045 020 3R** A100 Double Vane Pump T67DC € 3,688.00 024-92412-0 CARTR T67DC UNIT D 045 CW S1 Cam Ring 'P1' 045 - Cartridge Kit € 1,315.30 S24-10859-0 CARTR T67DC UNIT C 020 CW S1 Cam Ring 'P2' 020 - Cartridge Kit € 952.70 S24-40234-0 SHAFT T67DC SPLIN 3 ASS Shaft Assembly #3 (incl. Bearing) € 266.20 S14-42518-0 KIT T67DC SEAL S1 Seal Class S1 - Seal Kit € 52.30 S24-10170-0.

Data Continue to Demonstrate the Durability and Safety of a Novel Gene Therapy Approach to Treating Wet AMD MENLO PARK, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today will present updated preclinical data on ADVM-022 in non-human primate models of wet AMD (wAMD). Vascular endothelial growth factor (VEGF) overexpression plays a key role in the development and progression of wAMD as well as other retinal conditions. ADVM-022 utilizes a novel vector designed to allow for intravitreal delivery of gene sequences encoding an inhibitor of VEGF activity.

Programmu Asdv 020

Intravitreal delivery is the route of administration for current standard of care anti-VEGF therapies, and is preferred over invasive surgical subretinal delivery of gene sequences. Mehdi Gasmi, Ph.D., Chief Science and Technology Officer at Adverum will present updated data today at 2 p.m. ET at the Targeting Ocular Disorders conference taking place in Boston, MA September 27–28, 2017. Previously reported data using the industry standard, laser-induced choroidal neovascularization (CNV) model in a non-human primate study demonstrated that a single intravitreal administration of ADVM-022 had comparable efficacy in reducing grade IV CNV lesions to an intravitreal injection of standard-of-care anti-VEGF therapies.

In addition, data showed durable anti-VEGF protein expression with therapeutic protein levels at least 20 weeks after a single intravitreal administration of ADVM-022. Today, additional pharmacokinetic data are being presented, demonstrating sustained expression for 52 weeks, with only mild ocular inflammation following a single intravitreal administration of ADVM-022 in one non-human primate.

In a separate study, sustained expression for at least seven months has been observed in several non-human primates. Adverum will continue to monitor these non-human primates to assess long-term durability of sustained expression of anti-VEGF protein after a single administration of ADVM-022.

“These additional long-term data continue to demonstrate sustained expression of anti-VEGF protein and that our novel vector enables intravitreal delivery,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “Today, patients living with wAMD undergo frequent intravitreal injections, which can increase the burden of managing this disease and poor compliance with treatment can lead to vision loss. We believe the potential of a single intravitreal injection will be of great benefit to patients and clinicians.” About Adverum Biotechnologies, Inc. Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.